Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D, spoke with Managed Healthcare Executive, talks about the possible impacts ...

The funding agency aims to cap “indirect costs” in biomedical research grants. But this behind-the-scenes work is crucial to making research happen.

Devyser Diagnostics AB (DVYSR) reported its first profitable quarter as a public company in Q4 2024, with revenue reaching SEK 64.2 million, marking a 41.5% year-over-year increase. This achievement ...